Synthetic Cannabinoid K2 Overdoses Are Rampant. Here’s Why.

NIDA pharmacologist Michael Baumann explains how “unscrupulous vendors” hijacked compounds used in neuroscience and turned them into dangerous drugs.

Written byAshley Yeager
| 5 min read
Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

On Wednesday and Thursday (August 15 and August 16), more than 85 people in New Haven, Connecticut, overdosed on synthetic cannabinoids. In Washington, DC, last month, more than 300 people overdosed on the drugs, commonly called K2 or Spice, with similar cases reported in Baltimore, Brooklyn, and Los Angeles. In 2016, California Governor Jerry Brown banned possession of the synthetic drugs in his state, and in 2015, Mayor Bill de Blasio made it illegal to sell them in the boroughs of New York City. Still, such legislation hasn’t mitigated the overdoses in New York and other areas.

Michael Baumann, a pharmacologist at the National Institute on Drug Abuse who has been studying the effects of synthetic cannabinoids in animal models, tells The Scientist that part of the problem is that K2, Spice, and similar drugs are often referred to as fake marijuana, which can entice people to try it. After ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Ashley started at The Scientist in 2018. Before joining the staff, she worked as a freelance editor and writer, a writer at the Simons Foundation, and a web producer at Science News, among other positions. She holds a bachelor’s degree in journalism from the University of Tennessee, Knoxville, and a master’s degree in science writing from MIT. Ashley edits the Scientist to Watch and Profile sections of the magazine and writes news, features, and other stories for both online and print.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies